主页 > 医学信息 >
【medical-news】贫血药会诱发白血病？
Anemia drugs from Amgen and Johnson & Johnson may raise the risk that patients with a bone marrow disease will later develop leukemia, according to an analysis of 30 years of patient records.
Mayo Clinic researchers reviewed records of 311 patients with primary myelofibrosis, a scarring of the bone marrow, from 1976 to 2006. The drugs — Aranesp and Epogen from Amgen and Procrit from Johnson & Johnson — were linked to leukemia among 27 patients who developed the disease, according to research presented yesterday at the American Society of Hematology meeting in Atlanta.
Past studies linked anemia drugs to heart attack, stroke and death when used in high doses. Warnings from regulators about the risks caused sales of Aranesp in the United States to drop 36 percent in the third quarter. Aranesp is Amgen’s biggest product, with $4.12 billion in sales in 2006.
The study also found a higher risk of leukemia among patients who took danazol, a modified form of testosterone. Risk was also higher for patients with a high count of immature leukemia cells and a low number of platelet cells in the blood. Patients who took other treatments, like thalidomide and interferon-alpha, had no higher risk, researchers said.
Patients with primary myelofibrosis feel fatigued, and they sometimes take an anemia drug to stimulate growth of oxygen-carrying red blood cells.
The findings needed to be confirmed in a trial to answer the question about anemia drug risk, Dr. Ayalew Tefferi, a Mayo Clinic hematologist and the study’s lead investigator, said in a statement.
“While we cannot take these findings as an absolute, at the same time, they cannot be ignored,” Dr. Tefferi said. “Treatment decisions regarding the use of anemia drugs in patients with primary myelofibrosis should carefully be evaluated.”
http://www.nytimes.com/2007/12/11/business/11anemia.html?ref=health Mayo Clinic Study Links Anemia Drugs to Leukemia Risk
梅奥研究所发现贫血药和白血病风险之间存在联系
Anemia drugs from Amgen and Johnson & Johnson may raise the risk that patients with a bone marrow disease will later develop leukemia, according to an analysis of 30 years of patient records.
根据一份30多年的患者病历档案分析，阿目金公司和强生公司生产的贫血药可能会增加患有骨髓疾病的患者的白血病风险。
Mayo Clinic researchers reviewed records of 311 patients with primary myelofibrosis, a scarring of the bone marrow, from 1976 to 2006. The drugs — Aranesp and Epogen from Amgen and Procrit from Johnson & Johnson — were linked to leukemia among 27 patients who developed the disease, according to research presented yesterday at the American Society of Hematology meeting in Atlanta.
梅奥研究所的研究人员审查了1976到2006年间311名初期骨髓纤维变化患者的病历纪录。昨天在亚特兰大举行的美国社会血液学会议上发表的研究表明，这些抗贫血药物-阿目金公司生产的Aranesp和Epogen(红细胞生成素针剂) 以及强生公司生产的Procrit（重组人类红细胞生成素）-与27名患者的白血病之间存在联系。
Past studies linked anemia drugs to heart attack, stroke and death when used in high doses. Warnings from regulators about the risks caused sales of Aranesp in the United States to drop 36 percent in the third quarter. Aranesp is Amgen’s biggest product, with $4.12 billion in sales in 2006.
以往的研究表明当贫血药大剂量使用时，会导致心脏病发作，中风甚至死亡。监管署关于白血病风险的警告导致Aranesp 在美国的销量第三个季度下降了36个百分点。Aranesp是阿目金公司最主要的产品，2006年的销售额是41.2亿美元。
The study also found a higher risk of leukemia among patients who took danazol, a modified form of testosterone. Risk was also higher for patients with a high count of immature leukemia cells and a low number of platelet cells in the blood. Patients who took other treatments, like thalidomide and interferon-alpha, had no higher risk, researchers said.
研究同时指出患者使用炔羟雄烯唑——睾丸激素的一种修饰化合物——存在更高的白血病风险。那些血液中含有高水平的不成熟的白血病细胞及低水平的血小板细胞的患者的风险更大。研究者指出，患者采用其他的治疗药物，比如萨利多胺或干扰素，所带来的风险要小一些。
Patients with primary myelofibrosis feel fatigued, and they sometimes take an anemia drug to stimulate growth of oxygen-carrying red blood cells.
初期骨髓纤维化的患者容易感觉疲劳，他们有时会服用贫血药来刺激携氧红细胞的生长。
The findings needed to be confirmed in a trial to answer the question about anemia drug risk, Dr. Ayalew Tefferi, a Mayo Clinic hematologist and the study’s lead investigator, said in a statement.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-18 05:11
医学,生命科学网